» Articles » PMID: 9290705

Analysis of Genetic Alterations in Uterine Leiomyomas and Leiomyosarcomas by Comparative Genomic Hybridization

Overview
Journal Mol Carcinog
Date 1997 Aug 1
PMID 9290705
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Uterine leiomyomas are the most prevalent tumor type in women of reproductive age and are the most common reason for hysterectomies. Although uterine leiomyomas are considered to be benign, they are a major public health concern for women. In contrast, leiomyosarcomas are rare but highly malignant uterine tumors. They may arise in uteri with preexisting leiomyomas and histologically sometimes resemble leiomyomas, thus causing controversy about whether leiomyosarcomas arise within leiomyomas. In this study, we used comparative genomic hybridization (CGH) to identify genetic alterations unique to each tumor type and alterations that are common between the two tumors. We analyzed 14 cases of uterine leiomyomas and eight cases of uterine leiomyosarcomas. Only two of the 14 leiomyomas exhibited genetic alterations, and those were restricted to gains on chromosomes 14 and 19 and losses on chromosomes 1 and 4. In addition, 68 leiomyomas were examined for loss of heterozygosity on chromosomes 1 and 4, and only three tumors exhibited any losses. In contrast, all eight leiomyosarcomas showed gains and losses of DNA by CGH, and in many cases multiple changes were observed. The most commonly observed genetic aberration, occurring in five tumors, was gains on both arms of chromosome 1, suggesting that this chromosome contains loci involved in the development of leiomyosarcoma. Our results do not provide evidence for the progression from benign leiomyoma to malignant leiomyosarcoma. Moreover, the large number of random chromosomal alterations in the leiomyosarcomas suggests that increased genetic instability plays a role in the formation of these tumors.

Citing Articles

A View on Uterine Leiomyoma Genesis through the Prism of Genetic, Epigenetic and Cellular Heterogeneity.

Koltsova A, Efimova O, Pendina A Int J Mol Sci. 2023; 24(6).

PMID: 36982825 PMC: 10056617. DOI: 10.3390/ijms24065752.


Magnetic Nanoparticles as a Component of Peptide-Based DNA Delivery System for Suicide Gene Therapy of Uterine Leiomyoma.

Shtykalova S, Egorova A, Maretina M, Baranov V, Kiselev A Bioengineering (Basel). 2022; 9(3).

PMID: 35324801 PMC: 8945779. DOI: 10.3390/bioengineering9030112.


Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison.

Koltsova A, Efimova O, Malysheva O, Osinovskaya N, Liehr T, Al-Rikabi A Biomedicines. 2021; 9(12).

PMID: 34944592 PMC: 8698342. DOI: 10.3390/biomedicines9121777.


Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline :c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau M, Reisle C, Zhao E, Martin L, Alwelaie Y, Mungall K Cold Spring Harb Mol Case Stud. 2017; 3(5).

PMID: 28514723 PMC: 5593158. DOI: 10.1101/mcs.a001628.


Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Liegl-Atzwanger B, Heitzer E, Flicker K, Muller S, Ulz P, Saglam O Mod Pathol. 2016; 29(10):1262-77.

PMID: 27363490 DOI: 10.1038/modpathol.2016.107.